The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...

AstraZeneca has increased its investment in U.S. operations more than 14-fold, committing $50 billion to a range of ...

"attachment_1199068" align="aligncenter" width="1456"] A pharmacy worker distributing prescription medicines to ...

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...

The phase 3 trial randomized 260 people with anti-acetylcholine receptor antibody-positive gMG to take gefurulimab or placebo. After 26 weeks, people on gefurulimab performed significantly better on a ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

The U.K.-based drugmaker plans to invest $50 billion in the United States as the industry seeks to appease President Trump.

In a vote of confidence for Virginia’s growing life sciences sector, pharmaceutical giant AstraZeneca announced plans to ...

AstraZeneca's shares are up 3.5% over the year to date but remain down 11% over the past 52 weeks.